moderate or severe activity of systemic lupus erythematosus (SLE) research hub

A multicenter, randomized clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE)

This study compares two medicines, certolizumab pegol and belimumab, for people with moderate or severe lupus. Doctors want to see which medicine works better and is safer over 52 weeks to help manage the condition.